Approval of Ordspono is based on data demonstrating robust and durable responses in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, including in the post-CAR-T setting Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission TARRYTOWN, N.Y., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Eur ...

20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from landmark Phase 3 trials for Dupixent in COPD reinforce exacerbation reduction and improvement in lung function compared to placebo, and provide new assessments on health-related quality of life across patient subgroups Additional presentations spotlight a novel asthma imaging study showing the early impact of Dupix ...

Regeneron Pharmaceuticals, Inc. (REGN) announced that it has received a complete response letter (CRL) from the FDA for its biologics license application (BLA) for pipeline candidate linvoseltamab.The BLA is seeking FDA approval of linvoseltamab for the treatment of relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies.Regeneron stated that the sole issue identified in the CRL is related to findings from a pre-approval inspection at a third-party fill/finis ...

TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for linvoseltamab in relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. This anticipated outcome was previously disclosed during Regeneron’s second quarter 2024 earnings call. The sole approvability issue i ...

The biotech sector focuses on developing innovative medical treatments using biological processes. These companies research and create new drugs, therapies, and medical devices. Biotech stocks represent ownership in these cutting-edge firms. The sector is known for its potential to revolutionize healthcare and generate significant returns. However, it’s also associated with high risk due to the complex nature of drug development.Investing in biotech stocks can offer several advantages. These stocks have the ...

Would a stock split help lead Regeneron Pharmaceuticals shares higher?Regeneron Pharmaceuticals (REGN -1.00%) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price, making it more accessible to investors who can't buy fractional shares, or who simply don't want to do so. It would also give the stock some great, positive free press, which could potentially lead to even more of a rally.Should investors expect ...

PM Images Regeneron's Q2 Surge: Blockbuster Drugs Drive Revenue Growth Regeneron (NASDAQ:REGN) is up another 13% since my most recent "buy" recommendation in March. Seeking Alpha My last article covered Q4 '2023 earnings, which revealed strong performances from blockbuster drugs like Eylea, Libtayo, and Dupixent. In Q2 2024, it was more of the same for the $100 billion-plus pharmaceutical giant. Revenue grew 12% year-over-year, reaching $3.55 billion. The growth was, again, inspired by strong performances f ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conf ...

Regeneron (REGN) reported $3.55 billion in revenue for the quarter ended June 2024, representing a year-overyear increase of 12.3%. EPS of $11.56 for the same period compares to $10.24 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.38 billion, representing a surprise of +4.84%. The company delivered an EPS surprise of +9.37%, with the consensus EPS estimate being $10.57. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Regeneron Pharmaceuticals, Inc. (REGN) reported earnings per share (EPS) of $11.56, which beat the Zacks Consensus Estimate of $10.57. The company recorded an EPS of $10.24 in the year-ago period.The upside in the bottom line can be attributed to higher revenues.Total revenues increased 12% year over year to $3.54 billion, fueled by higher Dupixent, Eylea HD and Libtayo sales. Revenues also beat the Zacks Consensus Estimate of $3.38 billion. Shares are trading up in response to the better-than-expected resu ...